1
00:00:02,200 --> 00:00:05,555
Tesamorelin begins our growth and hormonal
signaling collection

2
00:00:05,580 --> 00:00:09,295
with fat that a bathroom scale cannot
distinguish.

3
00:00:09,320 --> 00:00:12,900
Visceral fat surrounds internal organs.

4
00:00:13,720 --> 00:00:16,380
Subcutaneous fat lies beneath the skin.

5
00:00:17,180 --> 00:00:20,040
Measuring one is different from measuring
total body weight.

6
00:00:20,620 --> 00:00:24,995
Developed by Theratechnologies in
Montreal, tesamorelin is a

7
00:00:25,020 --> 00:00:28,495
modified, forty-four-amino-acid version of

8
00:00:28,520 --> 00:00:30,280
growth-hormone-releasing hormone.

9
00:00:31,080 --> 00:00:34,435
The United States first approved Egrifta
in twenty ten

10
00:00:34,460 --> 00:00:39,655
for excess abdominal fat in adults with
HIV-associated

11
00:00:39,680 --> 00:00:41,420
lipodystrophy.

12
00:00:41,880 --> 00:00:44,795
It acts at the pituitary, encouraging the
body to

13
00:00:44,820 --> 00:00:49,095
release growth hormone and increasing
IGF-1.

14
00:00:49,120 --> 00:00:53,095
It stimulates a signaling pathway rather
than supplying growth

15
00:00:53,120 --> 00:00:54,280
hormone itself.

16
00:00:55,020 --> 00:00:58,835
In a randomized trial led by Julian Falutz
and

17
00:00:58,860 --> 00:01:02,635
colleagues, four hundred twelve adults
with HIV and abdominal

18
00:01:02,660 --> 00:01:07,975
fat accumulation received tesamorelin or
placebo for twenty-six

19
00:01:08,000 --> 00:01:09,000
weeks.

20
00:01:09,780 --> 00:01:14,195
CT measurements showed average visceral
fat falling fifteen point

21
00:01:14,220 --> 00:01:18,435
two percent with tesamorelin, while
placebo increased five

22
00:01:18,460 --> 00:01:19,400
percent.

23
00:01:19,760 --> 00:01:23,255
These were changes in a defined tissue
measurement, not

24
00:01:23,280 --> 00:01:25,220
percentages of total body weight.

25
00:01:25,880 --> 00:01:27,340
The approved use is specific.

26
00:01:28,120 --> 00:01:31,100
Tesamorelin is not indicated for
weight-loss management.

27
00:01:31,780 --> 00:01:36,755
Elevated IGF-1, fluid retention and
glucose intolerance

28
00:01:36,780 --> 00:01:38,260
require attention.

29
00:01:39,240 --> 00:01:42,755
Active cancer and pregnancy are among its
contraindications.

30
00:01:42,780 --> 00:01:47,220
Long-term cardiovascular safety has not
been established.

31
00:01:48,080 --> 00:01:51,815
Connect the medicine to its studied
population and measured

32
00:01:51,840 --> 00:01:52,560
outcome.

33
00:01:53,260 --> 00:01:56,895
These findings do not establish an
anti-aging or bodybuilding

34
00:01:56,920 --> 00:01:57,495
benefit.

35
00:01:57,520 --> 00:02:00,960
World Peptide Foundation.

36
00:02:01,820 --> 00:02:03,715
Peptides in 2.

37
00:02:03,740 --> 00:02:04,840
Every experience matters.